Do Queensland patients need both a TGA approval and a state Queensland Health approval to access medicinal cannabis?

For Schedule 8 products (high-THC preparations), a Queensland prescriber must comply with both the federal TGA pathway — either SAS-B self-assessment or the Authorised Prescriber route — and Queensland Health's state-level controlled-drug prescribing requirements. The two layers operate in parallel, not in sequence. For Schedule 4 low-dose CBD products, the state requirements are less onerous, but a prescription is still mandatory.

Can a GP in Queensland prescribe medicinal cannabis, or does it require a specialist?

Any registered medical practitioner — including a GP — can prescribe medicinal cannabis through the SAS-B pathway, provided they self-assess that the clinical circumstances are appropriate and fulfil both TGA notification requirements and Queensland Health's controlled-drug prescribing conditions. The Authorised Prescriber pathway typically requires specialist college endorsement, which tends to favour specialists, but GPs are not excluded from the SAS route.

Does a valid medicinal cannabis prescription protect a Queensland driver from a positive roadside drug test?

No. Queensland roadside testing under the Transport Operations (Road Use Management) Act 1995 tests for the presence of THC, not impairment or prescribed use. A valid prescription does not provide an exemption from detection at the roadside. The legal implications of that distinction may be considered in subsequent proceedings, but the detection itself is not affected by prescription status. Patients should seek specific legal advice about their individual circumstances.

What is QScript and does it apply to medicinal cannabis in Queensland?

QScript is Queensland's real-time prescription monitoring system. It records the dispensing of Schedule 8 controlled substances, including Schedule 8 medicinal cannabis products. Both prescribers and dispensing pharmacists can access QScript records. It is designed to support safe prescribing and dispensing practice for controlled drugs across the state.

Are all medicinal cannabis products in Australia required to meet Good Manufacturing Practice (GMP) standards?

Yes. Products supplied through TGA access pathways — whether domestically manufactured or imported — must comply with GMP standards. This applies equally to products supplied in Queensland. GMP compliance covers manufacture, testing, storage, and documentation. Queensland does not have a separate state-level GMP requirement that overrides the federal standard.

Medicinal Cannabis Access in Queensland: The Rules

By Marcus Hale · 20 May 2026 · 9 min read

Grand neoclassical building with columns and ornate facade.

Roughly 350,000 Australians now hold active medicinal cannabis approvals, according to TGA approval data published through 2024. Queensland accounts for a significant share of that figure, and yet there is still genuine confusion about medicinal cannabis access: whether the product named on a prescription is legal under state law, federal law, or both. The short version is that it's both, layered, and the layers matter.

The rules sit across several instruments: the Queensland Health regulatory framework on one side and the national Poisons Standard on the other. Reading them side by side is not the most thrilling way to spend a Tuesday afternoon, but somebody has to map the thing clearly, and that is what this piece sets out to do. It is education about how regulation works, not a recommendation to seek or use any product.

How medicinal cannabis access works federally

Before Queensland's own rules come into view, the federal framework sets the floor. Medicinal cannabis products in Australia are governed by the Therapeutic Goods Act 1989 (Cth) and the Poisons Standard (the SUSMP; Standard for the Uniform Scheduling of Medicines and Poisons). If the scheduling system is new to you, our explainer on the Poisons Standard (SUSMP) covers how substances are sorted into schedules. Under that standard:

Cannabis products with a THC content above 0.5% or above 1% for industrial hemp-derived CBD are listed as Schedule 8 (Controlled Drug), meaning they are prescription-only and subject to controlled-drug monitoring requirements.
Low-dose cannabidiol products (CBD ≤ 150 mg per day) that meet specific criteria were down-scheduled to Schedule 4 (Prescription Only) from February 2021, still prescription-only, but not controlled.

The practical difference between those two tiers is the extra layer of control. A Schedule 8 listing brings record-keeping, storage and monitoring obligations that a Schedule 4 listing does not. More background on the lower tier is in CBD and down-scheduling in Australia.

There are two main federal access pathways for unapproved products. The Special Access Scheme (SAS) allows individual patient approvals, most commonly under the self-assessable SAS-B category for medicinal cannabis. The Authorised Prescriber pathway allows a specialist to seek ongoing approval to prescribe to a class of patients without filing individual applications. Both pathways require the prescribing doctor to determine clinical appropriateness; neither pathway constitutes a recommendation to seek a prescription. The legal logic behind both is set out in unapproved therapeutic goods: the legal basis.

A smaller number of products are listed on the Australian Register of Therapeutic Goods (ARTG) as registered goods; these sit outside the unapproved-product access framework entirely, though they remain prescription-only. The difference between the two categories is explained in the ARTG: registered vs unregistered medicines.

Where Queensland law enters the picture

Each Australian state and territory must mirror federal scheduling under their own Drugs and Poisons legislation, but they can add requirements on top. That is the core of the state-federal split, and it is why the same product can carry different practical obligations depending on where the prescriber works. For the general principle, see state vs federal drug regulation in Australia.

In Queensland, medicinal cannabis sits within the Health (Drugs and Poisons) Regulation 1996 and the Medicines and Poisons Act 2019, which commenced in stages. Queensland Health administers the state-level framework. Because the new Act was phased in, older and newer instruments have both been relevant at different times, which is one reason published summaries can quickly look dated.

For Schedule 8 cannabis products, Queensland requires prescribers to comply with state controlled-drug prescribing requirements. This means: using an authority prescription, noting specific patient identifiers, and in many cases obtaining a Queensland Health approval before prescribing, separate from any TGA approval already obtained. The state approval requirement has historically applied when a prescriber is not an Authorised Prescriber under the federal pathway, though the precise current rules are set out in Queensland Health's published guidance and change over time.

Queensland also participates in the real-time prescription monitoring programme, QScript, which allows dispensing pharmacists and prescribers to check a patient's controlled-substance prescription history. Schedule 8 cannabis products fall within QScript's scope. Access isn't just about getting a prescription written; the dispensing and monitoring layer is active, and it is easy to overlook when people think only about the TGA approval.

Who can prescribe, and what the process looks like

Any registered medical practitioner in Queensland can apply to prescribe a Schedule 8 medicinal cannabis product. General practitioners are not excluded. But the process involves multiple steps, and the number of steps depends on which pathway is used.

Under SAS-B, the prescriber self-assesses, lodges a notification with the TGA, and, for Schedule 8 products in Queensland, also satisfies state requirements. The Special Access Scheme Category B page walks through that pathway in more detail. Under the Authorised Prescriber route, the prescriber obtains endorsement from a human research ethics committee or a specialist college, then applies to the TGA; state notification obligations then apply at the prescribing stage. Our overview of the Authorised Prescriber Scheme explains how that endorsement step fits in.

Nurse practitioners may also prescribe in some circumstances, subject to their scope-of-practice endorsement and Queensland Health requirements.

One common mistake is to assume that a TGA approval is the end of the process. It is not; in Queensland it can be one of two separate approvals. The rules here are genuinely more complex than the federal layer alone, and I'd argue that is where much of the confusion originates. A prescriber who expects one approval process can find there are two, and the second is administered by a different body under different legislation. A patient trying to follow the process has little chance of working this out without it being explained.

Product supply: imported, domestic and dispensed

Most medicinal cannabis supplied in Australia is imported, though domestic cultivation and manufacturing has grown since the Narcotic Drugs Amendment Act 2016 opened the door. All products supplied through TGA pathways must comply with Good Manufacturing Practice (GMP) standards, which govern how a product is made, tested and documented. Queensland suppliers and pharmacies operate within the same GMP and import permit framework as the rest of the country; there is no Queensland-specific manufacturing licence that overrides federal requirements.

Products vary considerably in composition. Some are full-spectrum preparations containing a range of cannabinoids alongside the primary active. Others are broad-spectrum or isolate-based. The regulatory classification turns primarily on THC content and dose, not on whether a product is full-spectrum or isolate, though the composition affects how the product is scheduled. For the broader grouping system used in Australia, see medicinal cannabis product categories.

Medicinal cannabis is dispensed through community pharmacies and, in some cases, hospital pharmacies. Not every pharmacy stocks these products routinely. Because they are controlled substances with cold-chain and security requirements, smaller pharmacies may need to order on a patient-by-patient basis. This is a practical reality, not a legal barrier, but it does affect how quickly a patient receives their dispensed product after the prescription is written.

Queensland pharmacists dispensing Schedule 8 products must record the supply in QScript. A pharmacist who has reasonable grounds to be concerned about a prescription, for instance apparent duplication, may decline to dispense and refer the matter appropriately. This is standard controlled-drug practice Australia-wide, and it is a safeguard rather than an obstacle.

Driving, drug testing and Queensland law

This is the section where I'd ask anyone reading to pay particular attention, because it's an area where federal medical approval and Queensland road law diverge sharply.

Roadside drug testing in Queensland under the Transport Operations (Road Use Management) Act 1995 tests for the presence of THC, not impairment, not therapeutic use, but detection. A valid prescription does not exempt a driver from a positive roadside test result. Queensland Police Service testing does not distinguish between illicit and prescribed use at the point of detection; that distinction may be relevant later in any legal proceeding, but it does not prevent a charge at the roadside.

The reason this catches people out is structural. The TGA and the prescribing framework are concerned with whether a product is appropriate for a patient and how it is supplied. Road transport law is concerned with whether a substance is present in a driver. The two systems were built for different purposes, and a medical approval simply does not carry across into the road-law setting.

My view, and I'll be direct about this, is that the disconnect between medical approval frameworks and road transport law has not been resolved in a way that adequately accounts for patients who rely on Schedule 8 products. It is a genuine policy gap. But it is the current legal position in Queensland, and it needs to be stated clearly. Anyone with questions about their own circumstances should raise them with their prescriber and seek proper legal advice rather than rely on a general article.

Staying current as the rules change

Queensland Health reviews and updates its controlled-drug prescribing requirements periodically. The TGA has also revised the SAS-B self-assessment criteria for medicinal cannabis more than once since the pathway opened in 2016. Anyone relying on this overview, including prescribers, should confirm current requirements directly with Queensland Health's Medicine Regulation and Quality branch and the TGA's published guidance before making any clinical or regulatory decision. If you are comparing jurisdictions, the neighbouring-state pages, such as medicinal cannabis access in NSW, show how the state layer differs elsewhere.

Understanding the pharmacology that underlies these products, how cannabinoids interact with the endocannabinoid system, and how bioavailability varies by formulation and route of administration, is a separate question from access law. But the two are related: the scheduling of a product turns partly on its composition and partly on dose, so a basic familiarity with cannabinoid classification is useful context for anyone reading product approvals. It also helps to know that evidence quality matters when reading about any of this; regulatory approval of a pathway is not the same as proof of benefit, and nothing here should be read as a therapeutic claim. Advertising of these products is tightly restricted too, as covered in advertising rules for therapeutic goods.

The framework has moved fast. As recently as 2016 there was no legal domestic access pathway to speak of. It is now a functioning system with tens of thousands of active approvals in Queensland alone. For national figures, patient access data in Australia sets out what is published. Whether the prescribing approval layers, federal plus state, are appropriately streamlined is a reasonable question, and one Queensland Health and the TGA are, as far as I can tell, actively looking at. Watch that space.

Sources

Marcus Hale, Regulatory researcher, TGA & access law

Common questions

Do Queensland patients need both a TGA approval and a state Queensland Health approval to access medicinal cannabis?: For Schedule 8 products (high-THC preparations), a Queensland prescriber must comply with both the federal TGA pathway — either SAS-B self-assessment or the Authorised Prescriber route — and Queensland Health's state-level controlled-drug prescribing requirements. The two layers operate in parallel, not in sequence. For Schedule 4 low-dose CBD products, the state requirements are less onerous, but a prescription is still mandatory.
Can a GP in Queensland prescribe medicinal cannabis, or does it require a specialist?: Any registered medical practitioner — including a GP — can prescribe medicinal cannabis through the SAS-B pathway, provided they self-assess that the clinical circumstances are appropriate and fulfil both TGA notification requirements and Queensland Health's controlled-drug prescribing conditions. The Authorised Prescriber pathway typically requires specialist college endorsement, which tends to favour specialists, but GPs are not excluded from the SAS route.
Does a valid medicinal cannabis prescription protect a Queensland driver from a positive roadside drug test?: No. Queensland roadside testing under the Transport Operations (Road Use Management) Act 1995 tests for the presence of THC, not impairment or prescribed use. A valid prescription does not provide an exemption from detection at the roadside. The legal implications of that distinction may be considered in subsequent proceedings, but the detection itself is not affected by prescription status. Patients should seek specific legal advice about their individual circumstances.
What is QScript and does it apply to medicinal cannabis in Queensland?: QScript is Queensland's real-time prescription monitoring system. It records the dispensing of Schedule 8 controlled substances, including Schedule 8 medicinal cannabis products. Both prescribers and dispensing pharmacists can access QScript records. It is designed to support safe prescribing and dispensing practice for controlled drugs across the state.
Are all medicinal cannabis products in Australia required to meet Good Manufacturing Practice (GMP) standards?: Yes. Products supplied through TGA access pathways — whether domestically manufactured or imported — must comply with GMP standards. This applies equally to products supplied in Queensland. GMP compliance covers manufacture, testing, storage, and documentation. Queensland does not have a separate state-level GMP requirement that overrides the federal standard.